José Miguel Rivera Caravaca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7416540/publications.pdf

Version: 2024-02-01

103 papers 1,564 citations

377584 21 h-index 35 g-index

105 all docs

105
docs citations

105 times ranked 1939 citing authors

#	Article	IF	CITATIONS
1	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. Journal of General Internal Medicine, 2023, 38, 315-323.	1.3	2
2	Adherence to the â€~Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes—A Systematic Review and Meta-Analysis of 285,000 Patients. Thrombosis and Haemostasis, 2022, 122, 406-414.	1.8	219
3	Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. Europace, 2022, 24, 4-11.	0.7	2
4	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Realâ€world <i>vs</i> clinicalâ€ŧrial evidence. British Journal of Clinical Pharmacology, 2022, 88, 282-289.	1.1	8
5	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. Europace, 2022, 24, 202-210.	0.7	9
6	Novel insights in the relationship of gut microbiota and coronary artery diseases. Critical Reviews in Food Science and Nutrition, 2022, 62, 3738-3750.	5.4	14
7	Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Clinical Research in Cardiology, 2022, 111, 1040-1047.	1.5	6
8	Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors. Diabetes Research and Clinical Practice, 2022, 184, 109215.	1.1	0
9	Growth Differentiation Factor 15 in Cardiovascular Diseases: Predicting Bleeding after Cardiac Surgery and Beyond That!. Thrombosis and Haemostasis, 2022, 122, 657-660.	1.8	2
10	Occupational Therapy in Severe Mental Disorder—A Self-Controlled Quasi-Experimental Study. Healthcare (Switzerland), 2022, 10, 493.	1.0	1
11	Relation of the â€~Atrial Fibrillation Better Care (ABC) Pathway' to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. Journal of Personalized Medicine, 2022, 12, 487.	1.1	4
12	Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. European Journal of Clinical Investigation, 2022, 52, e13788.	1.7	5
13	Stress in Emergency Healthcare Professionals: The Stress Factors and Manifestations Scale. International Journal of Environmental Research and Public Health, 2022, 19, 4342.	1.2	6
14	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. European Journal of Internal Medicine, 2022, 98, 122-124.	1.0	1
15	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. Journal of Thrombosis and Thrombolysis, 2022, , 1.	1.0	O
16	Predicting heart failure in atrial fibrillation patients: What about using biomarkers?. American Heart Journal, 2022, 251, 32-32.	1.2	0
17	Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. International Journal of Clinical Practice, 2022, 2022, 1-9.	0.8	1
18	Incident arrhythmias, heart failure and cardiovascular outcomes with SGLT-2 inhibitor use in diabetic patients: Insights from a global federated electronic medical record database. Europace, 2022, 24, .	0.7	0

#	Article	IF	Citations
19	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Thrombosis and Haemostasis, 2021, 121, 1107-1114.	1.8	4
20	Clinical profile and prognosis in patients on oral anticoagulation before admission for COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13436.	1.7	45
21	Outcomes in VKAâ€treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs â€realâ€world'. International Journal of Clinical Practice, 2021, 75, e13888.	0.8	1
22	Experiencia de 7 años con la protesis aortica de rápido despliegue Edwards Intuity. Cirugia Cardiovascular, 2021, 28, 77-83.	0.1	0
23	Novel biomarkers in Alzheimer's disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 167-179.	2.7	9
24	Comparison of Aortic Gradient and Ventricular Mass after Valve Replacement for Aortic Stenosis with Rapid Deployment, Sutureless, and Conventional Bioprostheses. Cardiology, 2021, 146, 656-666.	0.6	2
25	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. Journal of Clinical Medicine, 2021, 10, 715.	1.0	9
26	Should we make the risk stratification process more complex in patients with atrial fibrillation?. Europace, 2021, 23, 978-978.	0.7	1
27	Validating scores predicting atrial fibrillation recurrence post catheter ablation in patients with concurrent atrial fibrillation and pulmonary diseases. Annals of Palliative Medicine, 2021, 10, 4299-4307.	0.5	3
28	Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thrombosis Research, 2021, 205, 1-7.	0.8	18
29	Relationship between sleep habits and academic performance in university Nursing students. BMC Nursing, 2021, 20, 100.	0.9	14
30	Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. European Heart Journal Quality of Care & Dinical Outcomes, 2021, 7, 330-339.	1.8	63
31	Mid-term outcomes of rapid deployment aortic prostheses in patients with small aortic annulus. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 695-701.	0.5	3
32	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. Journal of Clinical Medicine, 2021, 10, 3357.	1.0	4
33	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	1.8	7
34	Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. Cardiovascular Diabetology, 2021, 20, 176.	2.7	10
35	Relationship between multimorbidity and outcomes in atrial fibrillation. Experimental Gerontology, 2021, 153, 111482.	1.2	16
36	Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORPâ€AF Longâ€ŧerm General Registry. European Journal of Clinical Investigation, 2021, , e13709.	1.7	0

#	Article	IF	CITATIONS
37	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Frontiers in Cardiovascular Medicine, 2021, 8, 787235.	1.1	4
38	Short- and medium-term complications after emergency department treatment of patients with atrial fibrillation: design and internal validation of the CoSTuM risk scale. Emergencias, 2021, 33, 85-92.	0.6	0
39	Effectiveness of music therapy and progressive muscle relaxation in reducing stress before exams and improving academic performance in Nursing students: A randomized trial. Nurse Education Today, 2020, 84, 104217.	1.4	31
40	Oneâ€year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry. British Journal of Clinical Pharmacology, 2020, 86, 1052-1061.	1.1	7
41	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. Expert Opinion on Pharmacotherapy, 2020, 21, 1867-1881.	0.9	3
42	Letter by Ding et al Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillationâ€, Stroke, 2020, 51, e361-e362.	1.0	0
43	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 3645.	1.0	11
44	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. Expert Review of Precision Medicine and Drug Development, 2020, 5, 331-345.	0.4	0
45	A nurseâ€led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. International Journal of Clinical Practice, 2020, 74, e13634.	0.8	13
46	The COVID-19 Pandemic and Its Impact on Homebound Nursing Students. International Journal of Environmental Research and Public Health, 2020, 17, 7383.	1.2	74
47	Work Shift and Circadian Rhythm as Risk Factors for Poor Sleep Quality in Public Workers from Murcia (Spain). International Journal of Environmental Research and Public Health, 2020, 17, 5881.	1.2	6
48	Reliability and Validity of a Stress Scale in Public Employees from Murcia (Spain). International Journal of Environmental Research and Public Health, 2020, 17, 8894.	1.2	2
49	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 2360-2369.	1.4	8
50	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. Thrombosis and Haemostasis, 2020, 120, 1200-1207.	1.8	41
51	Influence of the matrix type over the concentration of GDF-15. Journal of Investigative Medicine, 2020, 68, 1402-1404.	0.7	0
52	A new tool to assess patients' comfort during hospitalization: The Hospital Discomfort Risk questionnaire. Journal of Nursing Management, 2019, 27, 1485-1491.	1.4	2
53	Incidence and causes of pacemaker implantation during postoperative period of aortic valve replacement with rapid deployment prosthesis. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1534-1540.	0.5	3
54	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thrombosis and Haemostasis, 2019, 119, 1901-1919.	1.8	57

#	Article	IF	CITATIONS
55	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke, 2019, 50, 1372-1379.	1.0	48
56	Galectin-3 and \hat{l}^2 -trace protein concentrations are higher in clinically unaffected patients with Fabry disease. Scientific Reports, 2019, 9, 6235.	1.6	1
57	ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists. REC: CardioClinics, 2019, 54, 165-172.	0.1	3
58	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open, 2019, 9, e033712.	0.8	3
59	Heart Failure and Cardiac Events: Is a Consecutive Measurement of Biomarkers a Simple and Practical Approach?. Thrombosis and Haemostasis, 2019, 119, 1891-1893.	1.8	5
60	Chronic Kidney Disease and Thirdâ€Generation P2Y ₁₂ Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. Journal of Clinical Pharmacology, 2019, 59, 295-302.	1.0	2
61	Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. European Journal of Internal Medicine, 2019, 61, 48-53.	1.0	19
62	EpidemiologÃa del mixoma cardiaco en una población española. Una serie quirúrgica de 30 años. Revista Espanola De Cardiologia, 2019, 72, 685-686.	0.6	0
63	Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis. Clinical Drug Investigation, 2019, 39, 275-283.	1.1	1
64	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 183-188.	0.2	3
65	Epidemiology of Cardiac Myxoma in a Spanish Population. A 30-year Surgical Series. Revista Espanola De Cardiologia (English Ed), 2019, 72, 685-686.	0.4	2
66	Riesgo emb \tilde{A}^3 lico, riesgo isqu \tilde{A} ©mico y riesgo hemorr \tilde{A}_i gico. Revista Espanola De Cardiologia Suplementos, 2019, 18, 3-8.	0.2	0
67	Reliability and validity of the student stress inventory-stress manifestations questionnaire and its association with personal and academic factors in university students. Nurse Education Today, 2018, 64, 156-160.	1.4	27
68	Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices. European Journal of Internal Medicine, 2018, 52, 54-59.	1.0	8
69	Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroftâ€Gault, Modification of Diet in Renal Diseaseâ€4, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. Journal of the American Heart Association, 2018, 7	1.6	16
70	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. European Journal of Clinical Investigation, 2018, 48, e12929.	1.7	5
71	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. International Journal of Clinical Practice, 2018, 72, e13069.	0.8	4
72	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 892-902.	1.1	66

#	Article	IF	CITATIONS
73	Quality of oral anticoagulation with vitamin K antagonists in â€real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace, 2018, 20, 1435-1441.	0.7	39
74	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry. Thrombosis and Haemostasis, 2018, 118, 279-287.	1.8	17
75	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics, 2018, 40, 114-122.	1.1	21
76	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World―vs Clinical Trials. Mayo Clinic Proceedings, 2018, 93, 1065-1073.	1.4	28
77	Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation. Circulation Journal, 2018, 82, 353-360.	0.7	5
78	Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematology, 2018, 23, 712-718.	0.7	О
79	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. Journal of General Internal Medicine, 2018, 33, 847-854.	1.3	14
80	Enhancing the â€real world' prediction of cardiovascular events and major bleeding with the CHA ₂ DS ₂ -VASc and HAS-BLED scores using multiple biomarkers. Annals of Medicine, 2018, 50, 26-34.	1.5	22
81	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in â€real-world' atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. International Journal of Cardiology, 2018, 254, 125-131.	0.8	18
82	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA 2 DS 2 -VASc and HAS-BLED. American Heart Journal, 2018, 197, 27-34.	1.2	8
83	Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 57-65.	1.0	21
84	Risk factors for mental workload: influence of the working environment, cardiovascular health and lifestyle. A cross-sectional study. BMJ Open, 2018, 8, e022255.	0.8	3
85	Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test. Circulation: Cardiovascular Interventions, 2018, 11, e007264.	1.4	2
86	Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines. PLoS ONE, 2018, 13, e0208069.	1.1	4
87	Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HASâ€BLED and GARFIELDâ€AF Bleeding Scores. Journal of the American Heart Association, 2018, 7, e009766.	1.6	23
88	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. Circulation Journal, 2018, 82, 1286-1292.	0.7	4
89	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World―in Patients With Atrial Fibrillation. American Journal of Cardiology, 2018, 122, 785-792.	0.7	12
90	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Scientific Reports, 2017, 7, 41565.	1.6	31

#	Article	IF	CITATIONS
91	Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. European Journal of Cardiovascular Nursing, 2017, 16, 696-703.	0.4	10
92	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2176-2181.	0.7	19
93	Hypertension and Atrial Fibrillation: Balancing Stroke and Bleeding Risks. American Journal of Hypertension, 2017, 30, 1063-1065.	1.0	13
94	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. Scientific Reports, 2017, 7, 12066.	1.6	16
95	Longâ€Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABCâ€Stroke and CHA ₂ DS ₂ â€VASc Scores. Journal of the American Heart Association, 2017, 6, .	1.6	42
96	Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation. Evidence-Based Medicine, 2017, 22, 154-155.	0.6	2
97	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opinion on Drug Safety, 2017, 16, 1051-1062.	1.0	24
98	Applicability of the modified CHA 2 DS 2 -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. European Journal of Internal Medicine, 2017, 38, e21-e22.	1.0	5
99	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. Biological Research for Nursing, 2017, 19, 198-205.	1.0	1
100	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thrombosis and Haemostasis, 2017, 117, 1448-1454.	1.8	74
101	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. Thrombosis and Haemostasis, 2017, 117, 2261-2266.	1.8	51
102	Long-term bleeding risk prediction in â€~real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. Thrombosis and Haemostasis, 2017, 117, 1848-1858.	1.8	56
103	Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. Oncotarget, 2017, 8, 80182-80191.	0.8	12